China SXT Pharmaceuticals, Inc. (SXTC)
| Market Cap | 10.20M -66.6% |
| Revenue (ttm) | 1.54M -15.4% |
| Net Income | -8.87M |
| EPS | -22.46 |
| Shares Out | 6.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,529 |
| Open | 1.585 |
| Previous Close | 1.600 |
| Day's Range | 1.540 - 1.600 |
| 52-Week Range | 1.250 - 2.580 |
| Beta | 1.96 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2019 |
About SXTC
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, ... [Read more]
Financial Performance
In fiscal year 2025, China SXT Pharmaceuticals's revenue was $1.74 million, a decrease of -9.73% compared to the previous year's $1.93 million. Losses were -$3.30 million, 6.62% more than in 2024.
Financial StatementsNews
China SXT Pharmaceuticals, Inc. Announces Share Re-classification
TAIZHOU, China, March 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the “Company” or “SXTC”), a specialty pharmaceutical company focusing on the research, development, ma...
China SXT Pharmaceuticals Inc trading halted, news pending
19:50 EST China SXT Pharmaceuticals (SXTC) Inc trading halted, news pending
Here’s Why China SXT Pharmaceuticals Stock (SXTC) Rocketed Today
China SXT Pharmaceuticals stock was up ahead of the company’s reverse stock split tomorrow.
China SXT Pharmaceuticals announces 1-for-150 share consolidation
China SXT Pharmaceutics announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-150, effective on February 3, 2026. The Company’s Class A ordinary…
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
TAIZHOU, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the “Company” or “SXTC”), a specialty pharmaceutical company focusing on the research, development, man...
China SXT announces initiative to apply AI tech across TCM supply chain
China SXT Pharmaceuticals (SXTC) announced as part of its Artificial Intelligence Insight Initiative to explore the application of Artificial Intelligence and related digital technologies across the T...
Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
New York, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, tod...
China SXT Pharmaceuticals announces $10M registered direct offering
China SXT Pharmaceuticals (SXTC) announced that it has entered into a definitive agreement with a single investor for the purchase and sale of an aggregate of 66.67M Class A ordinary…
China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering
TAIZHOU, China, Jan. 09, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the “Company”), today announced that it has entered into a definitive agreement with a single investor ...
Why Is Penny Stock China SXT (SXTC) Up Almost 200% Today?
Shares in China SXT Pharmaceuticals ($SXTC) staged a massive rally on Thursday afternoon after the Chinese traditional medicine company launched an initiative to integrate artificial intelligence-driv...
China SXT announces launch of Strategic AI Insights Initiative
China SXT Pharmaceuticals (SXTC) announced the launch of a Strategic Artificial Intelligence (AI) Insights Initiative. This initiative aims to integrate AI-driven analytics into the Company’s product ...
China SXT Pharmaceuticals files $600M mixed securities shelf
17:03 EST China SXT Pharmaceuticals (SXTC) files $600M mixed securities shelf
China SXT Pharmaceuticals regains compliance with Nasdaq
China SXT Pharmaceuticals (SXTC) announced that the Company received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market dated March 13, 2025, informing the Co...
China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency
TAIZHOU, China, March 17, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (Nasdaq: SXTC) (the “Company”), a specialty pharmaceutical company focusing on the research, development, manufactur...
China SXT Pharmaceuticals Inc trading resumes
09:39 EST China SXT Pharmaceuticals (SXTC) Inc trading resumes
China SXT Pharmaceuticals Inc trading halted, volatility trading pause
09:34 EST China SXT Pharmaceuticals (SXTC) Inc trading halted, volatility trading pause
China SXT Pharmaceuticals Inc trading halted, news pending
19:50 EST China SXT Pharmaceuticals (SXTC) Inc trading halted, news pending
China SXT Pharmaceuticals files $120M mixed securities shelf
16:52 EDT China SXT Pharmaceuticals (SXTC) files $120M mixed securities shelf
China SXT Pharmaceuticals receives noncompliance notification from Nasdaq
China SXT Pharmaceuticals announced that on October 3, the company received a notification letter from Nasdaq notifying the company that the minimum bid price per share for its ordinary shares…
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
Jiangsu, China, , Oct. 07, 2024 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (“SXTC” or the “Company”), (NASDAQ: SXTC) announced today that on October 3, 2024, the Company received a notificati...
China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule
TAIZHOU, China, Oct. 26, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, m...
China SXT Pharmaceuticals announces one-for-twenty-five reverse stock split
China SXT Pharmaceuticals announced that its Board of Directors has set the date of October 5, 2023 to be the effective date for the Company’s one-for-twenty-five reverse stock split of…
China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split
Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on October 5, 2023 Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on October 5, 2023
China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split
TAIZHOU, China, May 18, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, developmen...
China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million
TAIZHOU, China, March 14, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development,...